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simulate RA evolution after treatment with etanercept (basecase treatment), ada-
limumab or infliximab as first-line therapies and their associated costs over a
12-month time horizon. Therapy continuation or switch was evaluated at week 24.
Effectiveness measures were ACR70 response and quality adjusted life years
(QALYs) gained. Direct medical costs included biologics, concomitant drugs, med-
ical follow-up and adverse events management. Clinical response was extracted
from published literature, while costs were collected from Colombian public offi-
cial databases. Probabilistic sensitivity analyses were performed through Monte
Carlo Simulation second-order approach. RESULTS: In base case analysis esti-
mated effectiveness resulted in [ACR70, QALY]: etanercept [31.3%, 0.79]; adali-
mumab [18.1%, 0.77] and infliximab [12.8%, 0.73]. Expected mean costs per patient
were 23,065USD, 24,869USD and 25,853USD, respectively. In cost-effectiveness and
cost-utility analysis, etanercept was the less costly and the most effective alterna-
tive being cost-saving in all comparisons: 2789USD less than infliximab(most costly
alternative); 18.5% more patients met ACR70 response regarding infliximab(the
least effective alternatives); incremental utility reached -0.0576 versus infliximab.
Acceptability curves showed that etanercept regardless willingness to pay would
be the most cost-effective biologic. CONCLUSIONS: Due to its lower costs and
favorable effectiveness profile, etanercept is dominant regarding ACR70 response
and QALYs gained over other biologic treatments in the management of RA at
Colombian public health care system.
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OBJECTIVES: Oral glucosamine formulations are frequently used as a food supple-
ment for joint maintenance, with little supportive evidence. However, Glusartel, a
formulation of glucosamine (produced by Rottapharm), has been shown to in-
crease oral bioavailability and has been studied in over 7,000 patients, showing a
significant improvement in joint space narrowing and knee replacement. The cost-
effectiveness of the new product was studied compared to both standard of care
and other glucosamine products. METHODS: A four state (with death as a sink
state) Markov model was constructed to investigate disease progression, patient
utility (mapped from the Western Ontario and McMaster Universities Arthritis
Index (WOMAC)) and cost. Efficacy was taken from two pivotal trials, while costs
were taken from standard sources including NHS Reference Costs, PSSRU, and the
British National Formulary. All costs were inflated to financial year 2009/2010, with
the perspective taken that of NHS Scotland. RESULTS: Using a 50 year (lifetime)
time horizon, with patients beginning treatment at age 62 (as seen in the clinical
trials), patients treated with Glusartel are estimated to cost £1799 more than those
treated with standard management (£6443 vs. £4645), but gain an additional 0.15 (2
d.p.) QALYs (9.45 vs. 9.31), generating an ICER of £12,402. Compared with currently
used glucosamine treatment, even conservatively assuming equal efficacy, Glusar-
tel produces a cost saving of £700, and is dominant in outcomes when the assump-
tion around treatment efficacy is relaxed. The model is sensitive to the time hori-
zon, utility in mild/moderate arthritis and data source for costs, with the main
driver being the efficacy of Glusartel in delaying severe arthritis. CONCLUSIONS:
From the perspective of NHS Scotland Glusartel is highly cost-effective compared
to standard of care, and cost saving compared to other glucosamine products. By
revising existing prescribing patterns, NHS Scotland could both improve patient
outcomes, and realise cost savings.
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OBJECTIVES: To review relevant Rheumatoid Arthritis (RA) economic models for
biologics; and identify potential model limitations. METHODS: Search targeted
economic evaluations of RA biologics since 2000 using Medline, EMBASE, and Co-
chrane databases. Articles were subjected to a two level review process before data
abstraction. RESULTS: Twenty-six economic evaluations were published assessing
costs and outcomes associated with RA biologics. Most models used a payer per-
spective. Two methotrexate (MTX)-naïve patient models were cost utility analyses
(CUA); one was a patient simulation model and one a decision analytic model. Of
seventeen models for disease modifying anti-rheumatic drug (DMARD)/MTX fail-
ure populations, sixteen were CUAs and one was a cost-effectiveness (CE) model
based on cost/ACR improvement achieved; model structures included patient level
simulation, Markov, and decision analytic models. Of seven models identified for
anti-TNF inhibitor failure populations, five were CUAs and two were CE models
where CE was defined by both cost/remission and cost of achieving low disease
activity (Disease Activity Score (DAS)28 3.2); six models employed a simulation
structure and one a Markov structure. Results varied widely across studies due to
heterogeneity in the time horizon, perspectives, year of costs and comparators.
Model Incremental cost effectiveness ratios (ICERs) ranged from $4,849 (2007$)
$47,157 (2007$) per QALY for MTX-naïve, $14,518 (1998$) $498,420 (2005$) per
QALY for DMARD/MTX failure, and $12,869 (2006$)$76,363 (2008$) per QALY for
TNF-failure. Key limitations included limited availability of treatment data over
long time horizons, and use of Health Assessment Questionnaire (HAQ) as primary
outcome and as determinant of utility. CONCLUSIONS: We recommend future
modeling efforts evaluate the use of direct utilities versus mapping; advantages of
CUA versus CE and simulation approach using patient level data; benefits of longer
time horizon; and inclusion of both health related quality of life assessment such
as HAQ and disease activity such as DAS-28 as model inputs.
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OBJECTIVES: Half of patients with systemic juvenile idiopathic arthritis (sJIA) will
eventually fail to non-steroidal anti-inflammatory drugs (NSAIDs) or corticoste-
roids. Tocilizumab (TCZ) is indicated for patients with refractory sJIA. We aimed to
determine the cost and the effectiveness of adding TCZ to conventional treatment
for sJIA in Mexico. METHODS: We designed two decision models to compare TCZ
versus placebo. In each model, two time horizons were analyzed: 12 weeks and one
year. Target population consists of patients (2-19 years) with active sJIA and inad-
equate response to NSAIDs and corticosteroids. The dosing scheme for TCZ was
based on body weight: 8 mg/kg for patients 30 kg and 12 mg/kg for patients 30
kg. The analysis was performed under the perspective of the public health care
system in Mexico. Tocilizumab acquisition cost, infusion fees and standard man-
agement of sJIA according to level of response were evaluated. Efficacy was defined
in terms of the American College of Rheumatology Pediatric response criteria. Re-
source use and unit costs were gathered from local sources; efficacy was derived
from two phase-3 clinical trials; increase in mortality and utility scores associated
with level of response was based on literature. All costs are expressed in 2011 euros
(€). RESULTS: A markedly higher proportion of patients achieved an ACRPedi70
response with TCZ in both children with the possibility of maintaining methotrex-
ate (71% vs. 8%) and in those without that alternative (75% vs. 13%). The incremen-
tal cost per achieving an ACRPedi70 response was around 2400€ in both models.
During base-case, the incremental cost per Quality-Adjusted Life Year (QALY)
gained with TCZ ranged from 10,636€ to 10,681€. The gross domestic product per
capita in Mexico during 2010 was estimated at 7048€. Results were robust to vari-
ation in all parameters. CONCLUSIONS: TCZ is a cost-effective option to treat sJIA
in Mexico.
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OBJECTIVES: Rheumatoid Arthritis (RA) leads to significant impact on manage-
ment costs and patient’s quality of life. In Brazil, costs associated to RA patient’s
care are 6.6-fold higher than general population, with greater resources consump-
tion. Biologic treatment after two disease-modifying antirheumatic drugs fail is an
alternative, but their high cost represents a challenge for decision makers. Cur-
rently, adalimumab, etanercept and infliximab are provided by the Brazilian public
healthcare system. This study aims to assess the cost per responder of etanercept
versus adalimumab and infliximab, for moderate to severe rheumatoid arthritis
treatment from a public payer perspective in Brazil. METHODS: A decision-tree
model was developed to simulate RA evolution after treatment with etanercept
(basecase treatment), adalimumab or infliximab as first-line therapies and their
associated costs over a 12-month time horizon. Therapy continuation or switch
was evaluated at week 24. Effectiveness measure was ACR70 response. Direct med-
ical costs included biologics, concomitant drugs, medical follow-up and adverse
events management. Clinical response was extracted from published literature,
while costs were collected from Brazilian public official databases. Probabilistic
sensitivity analyses were performed through Monte Carlo Simulation second-order
approach. RESULTS: In basecase analysis, 31.4%, 18.2% and 12.9% patients met
ACR70 response for etanercept, adalimumab and infliximab. Annual costs per
ACR70 responder were 147,147USD, 264,097USD and 327,632USD, respectively. Et-
anercept represented the least costly per ACR70 responder and the most effective
alternative in all comparisons: 116,950USD and 180,485USD less than adalimumab
and infliximab, respectively; 13.2% and 18.5% more patients met ACR70 response
regarding adalimumab and infliximab.CONCLUSIONS: Etanercept exhibited incre-
mental clinical effectiveness at a lower cost per ACR70 responders when compared
to adalimumab and infliximab, from the Brazilian public health care system.
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OBJECTIVES: Alendronate is subsidised in Australia for patients with a prior frac-
ture or those aged 70 with a bone mineral density (BMD) T-score of -3.0. The
objective of the analysis was to assess the cost-effectiveness of broadening access
to alendronate to individuals aged  70 with BMD T–score  –2.5. METHODS: A
cost-utility analysis was constructed using a microsimulation model of a Markov
process. The comparator was ‘no alendronate’ until such time that the individual
became eligible for treatment due to a fracture or to BMD T-score reaching -3. The
microsimulation transits patients through six health states of a Markov process
with the health states defined by treatment status (not eligible, on treatment,
discontinued treatment) and fracture status (with or without history of fracture).
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As patients advance through the model, their BMD progresses and they are at risk
of fracture (hip, vertebral, other) and of death. BMD changes, fracture risks and
mortality were all based on the Dubbo Osteoporosis Epidemiology Study (DOES).
Utility values were based on the patients fracture status. Evidence for the efficacy
of alendronate in the prevention of fracture was the clinical fracture arm of the
Fracture Intervention Trial (FIT). RESULTS: The incremental cost per QALY of
broadening access to alendronate compared with current practice was $34,808
(incremental costs of $783 per patient with 0.0225 QALYs gained). Broadening ac-
cess to alendronate resulted in fewer fracture-related deaths (301 per 100,000 pop-
ulation), hip fractures (904), vertebral fractures (259) and other fractures (1098).
CONCLUSIONS: Broadening primary prevention treatment of osteoporotic fracture
with alendronate to individuals aged 70 years with BMD T–scores  – 2.5 will
prevent fractures and save lives at good value-for-money.
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OBJECTIVES: Increasing real-life adherence to bisphosphonates therapy is impor-
tant to achieve the clinical benefits of reducing fractures reported in randomized
clinical trials (RCTs). The aim of this pharmacoeconomic analysis was to determine
the cost-effectiveness of a pharmaceutical care intervention program in commu-
nity pharmacies, aimed to increase bisphosphonates adherence for the prevention
of osteoporotic fractures. METHODS: A decision analytical model was constructed
with a time horizon of three years, discounting at 4.0% and 1.5% annually for costs
and effects, respectively. A Dutch healthcare provider’s perspective was adopted.
Adherence and efficacy data were gathered from a Dutch pharmaceutical care
program in community pharmacies (the MeMO intervention). The association be-
tween bisphosphonate adherence and osteoporotic fractures was modelled using
Dutch clinical studies. Recent and upcoming reimbursement policy changes in The
Netherlands were modelled with a scenario of therapeutic substitution, character-
ized by drastically lower drug prices. RESULTS: Adherence to bisphosphonates
therapy in The Netherlands was 68.3%. The pharmaceutical care intervention pro-
gram increased bisphosphonates adherence to 83.9% (P0.001). If the intervention
program would be introduced nationwide in community pharmacies, 337 osteopo-
rotic fractures would be prevented and 47 quality-adjusted life years (QALYs)
would be gained. Additional medication and intervention costs were €1,738,000;
the cost-savings due to reduced fractures were €998,000. The cost-effectiveness of
the pharmaceutical care intervention was €16,000 per QALY. When drug prices
decline following therapeutic substitution policies, the intervention will be
cost-saving. CONCLUSIONS: Pharmaceutical care programs in community phar-
macies, such as the MeMO intervention, can improve bisphosphonate adherence,
resulting in a considerable number of osteoporotic fractures being prevented.
Therapeutic substitution policies that lower drug prices will increase the cost-
effectiveness of interventions that increase adherence. This study demonstrates
the value of pharmaceutical care programs in community pharmacies to increase
therapy adherence.
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OBJECTIVES: Dupuytren’s contracture (DC) is a progressive disorder that limits
hand function and impacts on patient’s ability to work or to perform their daily
activities. Current standard of care is limited fasciectomy, a surgical procedure that
removes part of the affected cord. Collagenase clostridium histolyticum (CCH) is the
first licensed pharmacological treatment for DC patients with a palpable cord. This
study aims to estimate costs of CCH versus fasciectomy in Portuguese DC patients.
METHODS: A cost minimization approach was adopted, with effectiveness as-
sumed to be equivalent for CCH and fasciectomy. Resource use was elicited
through a panel of five Portuguese experts with extensive clinical experience. Fa-
sciectomy’ direct costs of included surgery in-patient cost and post-surgery costs:
follow up outpatient visits and physiotherapy. CCH’ direct costs included vials
costs, administration of injection in an outpatient setting and a follow up outpa-
tient visit. Fasciectomy induced indirect costs were estimated by the human cap-
ital method. Unit costs were extracted from Portuguese literature and official
sources. Societal perspective was adopted. RESULTS: Average direct cost per pa-
tient for CCH and fasciectomy were respectively 2,099€ and 2,366€. Average saving
per patient is 267€, a reduction of 11% direct fasciectomy costs. Although inclusion
of indirect costs can introduce some uncertainty due to measurement error, they
should be analysed given their relevance to the society: average saving per patient
estimate is 1,407€ when we include productivity costs. CONCLUSIONS: CCH is a
convenient, minimally invasive, effective and generally well tolerated alternative
to surgery for DC’ patients. Adoption of CCH as an alternative to fasciectomy offers
a choice for DC’ patients, and provides an efficient approach to the treatment of DC
by reducing the demand for physiotherapy and in-patient services. On average,
CCH is cost saving in Portugal compared with fasciectomy and induces superior
savings when indirect costs are included.
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OBJECTIVES: Denosumab has been shown to be a cost-effective use of NHS re-
sources for the treatment of postmenopausal osteoporosis in England and Wales.
This study assessed the cost-effectiveness of denosumab given Scottish treatment
and resource use patterns. METHODS: A probabilistic model employed in a recent
submission to NICE was used with resource use amended to reflect local expert
advice. This indicated zoledronate requires an annual pre-infusion assessment
appointment and that patients failing on, or unable to take oral bisphosphonates
are referred to secondary care for advice on further treatment. Denosumab is mod-
elled as initiated in secondary care, with subsequent injections in primary care.
Fracture risk for 70 year old women with bone mineral density T-score 2.5 was
based on a published algorithm and accounted for prior fracture. Relative efficacy
of osteoporosis therapies was based on meta-analysis and adjusted indirect com-
parison. Utilities reflected patients’ age and modelled health states. All therapies’
administration was costed using NHS Reference and PSSRU costs. Drug costs were
from the British National Formulary. Costs and utilities were discounted at 3.5%.
RESULTS: Denosumab dominated strontium ranelate and IV ibandronate in both
cohorts, and was cost-effective versus raloxifene (£4,339/QALY without prior frac-
ture and dominant in patients with prior fracture). Denosumab was also cost-
effective against no treatment: cost/QALY £22,380 and £9,618 in patients without
and with prior fracture respectively. IV zoledronate and denosumab each produced
very similar QALYs in the two cohorts, however, denosumab’s costs were approx-
imately £1,000 lower in each. Zoledronate’s cost/QALY ratios against denosumab
were £120,000 and £50,000, i.e. zoledronate was not cost-effective against deno-
sumab. Denosumab had the greater probabilities of being cost-effective at thresh-
old values of £30,000/QALY in both cohorts. CONCLUSIONS: Denosumab was
shown to be cost-effective against all comparators in both primary and secondary
care settings. Compared with zoledronate, denosumab may be a better use of NHS
resources.
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OBJECTIVES: To evaluate the cost-utility and budget impact (BI) of certolizumab
pegol (CZP) as an add-on therapy to methotrexate (MTX) versus other first line
biological DMARDs, in the treatment of adult patients with active RA who did not
respond adequately to DMARDs, including MTX, in Greece. METHODS: A Markov
(cohort health state transition) model was developed to evaluate the cost-utility of
CZP versus other TNF- inhibitors recommended in Greece (etanercept [ETA], ada-
limumab [ADA] and infliximab [IFX]). Treatment efficacy was measured using the
ACR-responses (ACR20/50/70) at 6 months. ACR estimated rates were based on
adjusted indirect comparison (MTX as common comparator) of published clinical
trials. Utilities were derived from EQ-5D data from CZP RA clinical trials. Clinical
history/resource use data came from published literature. Sensitivity analyses
were conducted. The BI of CZP as an add-on therapy to MTX was estimated from
payer perspective over 2011–2015. The alternatives to CZP include all TNF- inhib-
itors recommended in Greece (etanercept, adalimumab, infliximab, golimumab).
Epidemiological data were used to estimate the RA population eligible for CZP
therapy. Published 2011 hospital unit costs (drug acquisition, administration, mon-
itoring, resources) in both analyses were taken from Greek routine sources/expert
opinion. Base case analysis assumed a payer perspective, costs discounted at 3.5%
(CU/BI), a lifetime horizon, with outcomes discounted at 3.5% (CU), 75kg patient-
fixed average weight (BI). RESULTS: Base case analysis indicated that CZP is cost-
effective compared with all combination therapies considered (at €60,000(3xGDP/
capita) willingness-to-pay threshold), with an incremental cost-effectiveness ratio
of €19,181/QALYs, €32,208/QALYs, €22,349/QALYs versus ADAMTX, ETAMTX
and IFXMTX, respectively. In terms of BI, the introduction of CZP on the Greek
market produced cumulative net savings of €7.68M during 2011–2015.
CONCLUSIONS: This analysis shows that CZPMTX is cost-effective versus. the
other TNF- inhibitors recommended in Greece for the treatment of RA and its use
is anticipated to result in budgetary net savings.
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OBJECTIVES: To evaluate the cost-utility of CZP compared with standard-of-care
first-line administered TNF-inhibitors  MTX in the treatment of moderate-to-
severe RA in Spain.METHODS:A Markov (cohort health state transition) model was
developed to evaluate the cost-utility of CZP versus the other TNF-inhibitors li-
censed and recommended in Spain (etanercept [ETA], adalimumab [ADA], and
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